Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT04140773
Other study ID # 2019-01699
Secondary ID
Status Terminated
Phase N/A
First received
Last updated
Start date November 25, 2021
Est. completion date August 31, 2022

Study information

Verified date September 2022
Source Psychiatric Hospital of the University of Basel
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

In psychotic disorders, negative symptoms and cognitive impairment are difficult to treat with antipsychotics, which are mostly effective for positive symptoms. However, it is important that negative symptoms and cognitive impairment are treated as well, as they both play a large part in the acute episode and long-term course of schizophrenia outcome. Previous studies have used D-serine as add-on treatment in patients with psy-chotic disorders and high-risk patients, with positive results. So far, no study has investigated the effects in a sample of recent-onset psychosis patients. Therefore, this study will include 30 patients (18-50 years old) with recent-onset psychosis. In addition to their regular treatment, patients will receive either D-serine (2 g/d) or placebo for 6 weeks. D-serine is an amino-acid naturally occurring in the brain which is prescription-free available as nutritional supplement. The primary outcome measure is total score on the Positive and Negative Syndrome Scale (PANSS). Secondary measure-ments include PANSS subscales, neurocognitive tests, (f)MRI, and EEG


Recruitment information / eligibility

Status Terminated
Enrollment 3
Est. completion date August 31, 2022
Est. primary completion date August 31, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 50 Years
Eligibility Inclusion Criteria: - Age 18-50 - Recent onset psychosis (< 5 years of overt psychotic symptoms) - Able to read and understand study procedures and participant's information Exclusion Criteria: - Clozapine use - Suicidal ideation - Psychotic disorders and symptoms associated with general medical conditions or substance abuse - BMI > 30 - Renal impairment (history and creatin levels (< 80 ug/L for woman and < 97 ug/L for men)) - Hearing impairment - Current or past (< 6 months) enrolment in another clinical trial with the primary outcome to improve symptoms - Pregnant or lactating women (pregnancy test)

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
D-serine
Capsule D-serine
Other:
Placebo
Capsule D-serine

Locations

Country Name City State
Switzerland UPK Basel Basel Basel-Stadt

Sponsors (1)

Lead Sponsor Collaborator
Dragos Inta

Country where clinical trial is conducted

Switzerland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Total symptom severity total score on the Positive and Negative Syndrome Scale (PANSS). Lower scores indicate better outcome (min. 30 - max. 120). change from baseline to 6 weeks
Secondary Subscales symptom severity Subscores (5-factor model) on the Positive and Negative Syndrome Scale (PANSS). Lower scores indicate better outcome. change from baseline to 6 weeks
Secondary Symptom severity and treatment response measured with the Clinical Global Impression Scale (CGI), lower scores indicate a better outcome change from baseline to 6 weeks
Secondary Resting-state microstates measured with resting-state electroencephalography (EEG). large-scale neural networks are investigated with EEG microstates Ocillations in the theta-band (4-7 Hz) and gamma-band (>30 Hz) will be assessed.
measured with resting-state electroencephalography (EEG). Ocillations in the theta-band (4-7 Hz) and gamma-band (>30 Hz) will be assessed.
change from baseline to 6 weeks
Secondary Mismatch Negativity (MMN) measured with EEG change from baseline to 6 weeks
Secondary Intelligence Part of neurocognitive testing. Higher scores indicate better outcome. change from baseline to 6 weeks
Secondary Attention and processing speed Part of neurocognitive testing. Higher scores indicate better outcome. change from baseline to 6 weeks
Secondary Executive functioning Part of neurocognitive testing. Higher scores indicate better outcome. change from baseline to 6 weeks
Secondary Memory Part of neurocognitive testing. Higher scores indicate better outcome. change from baseline to 6 weeks
See also
  Status Clinical Trial Phase
Completed NCT02306551 - Well Being And Resilience: Mechanisms of Transmission of Health and Risk
Active, not recruiting NCT00627029 - Evaluation of Programs of Coordinated Care and Disease Management N/A
Terminated NCT00049738 - Screening for Childhood-Onset Psychotic Disorders N/A
Withdrawn NCT01724372 - The Role of Antidepressants or Antipsychotics in Preventing Psychosis N/A
Completed NCT00716755 - Minimizing Doses of Antipsychotic Medication in Older Patients With Schizophrenia. N/A
Completed NCT00498550 - Treatment of Schizophrenia and Comorbid Cannabis Use Disorder: Comparing Clozapine to Treatment-as-Usual Phase 4
Completed NCT01473550 - Mental Health Engagement Network (MHEN) N/A
Completed NCT01207219 - Yoga and Aerobic Exercise in Psychosis N/A
Completed NCT00397033 - Evaluation of Effectiveness and Safety of Paliperidone Extended Release in Patients With Schizoaffective Disorder. Phase 3
Recruiting NCT04945278 - Study of Self-Recognition and Self/Other Distinction Disorders in Patients With Psychological Vulnerability N/A
Completed NCT03955250 - Mobile After-Care Support App: Pilot RCT N/A
Completed NCT00287352 - Study of Amantadine for Weight Stabilization During Olanzapine Treatment Phase 1
Completed NCT00005658 - Glycine to Treat Psychotic Disorders in Children Phase 2
Terminated NCT00169026 - Alcoholism and Schizophrenia: Effects of Clozapine Phase 4
Completed NCT00001482 - New Drugs in the Treatment of Mood Disorders Phase 2
Terminated NCT03671005 - Mindfulness-based Group Therapy for Inpatients With Schizophrenia Spectrum Disorders N/A
Completed NCT00095524 - Effects of Aripiprazole in Overweight Patients Treated With Olanzapine for Schizophrenia or Schizoaffective Disorder Phase 3
Completed NCT00156715 - Efficacy of Quetiapine in the Treatment of Patients With Schizophrenia and a Comorbid Substance Use Disorder Phase 4
Completed NCT03667729 - The Effects of Progressive Muscle Relaxation Therapy in Patients With Schizophrenia N/A
Completed NCT00001656 - Comparison of Clozapine vs Olanzapine in Childhood-Onset Psychotic Disorders Phase 4